News
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FEATURED STORIES
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
The data collected from the cut-off demonstrates that patients can maintain an average of 9.6 months without disease progression after the initial dosage of the tislelizumab-chemotherapy treatment.
To cope, life sciences companies are undertaking a supply chain risk assessment, conducting make-or-buy assessments, investing in supply chain technology and identifying backup suppliers.
Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.
Weeks after Imara announced its plans to discontinue the development of tovinontrinein for sickle cell and beta-thalassemia and heart failure, the company has culled 83% of its workforce.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
The Chinese government has halted the recommendation of Lianhua Qingwen used as a traditional Chinese treatment for mild cases of COVID-19.